Intelligence desk

Products

Signal Tracker Data Platform Data Enrichment API

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Stemedica Cell Technologies, Inc logo — Developing Breakthrough Progenitor Cell and Protein Therapeu...

Stemedica Cell Technologies, Inc

Developing Breakthrough Progenitor Cell and Protein Therapeutics

Founded 2005 United States San Diego, United States 16 employees Series B Total: $67.00M Biotechnology, Health Care

General Information

Company Name Stemedica Cell Technologies, Inc
Founded Year 2005
Location United States San Diego, United States +1
Employees 16
Industries Biotechnology, Health Care
Funding Stage Series B
Social

Get notified when Stemedica Cell Technologies, Inc moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Stemedica Cell Technologies, Inc

Stemedica Cell Technologies, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of progenitor cell and protein therapeutics for underserved medical conditions. The company has developed a proprietary manufacturing technology platform that produces allogeneic progenitor cell products with intellectual property protection under a low-oxygen, low-tension environment in a cGMP-compliant manufacturing facility. The company's lead drug candidate, ischemia-tolerant mesenchymal stem cells, or itMSCs, is an allogeneic progenitor cell therapy currently in clinical development for the treatment of ischemic stroke and Alzheimer’s disease. The company’s second drug candidate, ischemia-tolerant neural progenitor cells, or itNSCs, is an allogeneic cell therapy currently in development for spinal cord injury. Additionally, Stemedica is developing progenitor multi-cell therapy (itMSCs and itNSCs) for ischemic stroke and progenitor cell and protein combination therapy for Alzheimer’s disease. The company's last investment was a $22.00M Series B investment at 31 December 2009. Stemedica's innovative approach and promising drug candidates demonstrate potential for addressing significant unmet medical needs in the biotechnology and healthcare industries. For more information, visit www.stemedica.com

Taxonomy: biopharmaceutical, progenitor cell therapy, clinical-stage, stem cell technology, Alzheimer's disease treatment, ischemic stroke treatment, neural progenitor cells, cell therapy manufacturing, cGMP-compliant facility, clinical trials, regulatory compliance, proprietary manufacturing technology, government-licensed manufacturer, clinical-grade stem cells, medical indications

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $22.00M - 31 Dec 2009
Series A $45.00M - 20 May 2008

Stemedica Cell Technologies, Inc Alternatives & Competitors

Stemedica Cell Technologies, Inc vs
ViaCyte
ViaCyte United States

Regenerating Health: Transforming the lives of patients with insulin-requiring diabetes

Series D
35 employees
Biotechnology, Health Care
Stemedica Cell Technologies, Inc vs
Lineage Cell Therapeutics
Lineage Cell Therapeutics United States

A clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.

Post Ipo Equity
33 employees
Biopharma, Biotechnology
Compare Stemedica Cell Technologies, Inc vs Lineage Cell Therapeutics
Stemedica Cell Technologies, Inc vs
Cell BioEngines, Inc
Cell BioEngines, Inc United States

‘Off-the-Shelf’ Curative Cell Therapies

Pre Seed
3 employees
Biotechnology, Health and Wellness

FAQ About Stemedica Cell Technologies, Inc

Developing Breakthrough Progenitor Cell and Protein Therapeutics
Stemedica Cell Technologies, Inc was founded in 2005.
Stemedica Cell Technologies, Inc is headquartered in San Diego, United States.
Stemedica Cell Technologies, Inc operates in the following industries: Biotechnology, Health Care.
Stemedica Cell Technologies, Inc has approximately 16 employees.
Stemedica Cell Technologies, Inc has completed 2 funding rounds, raising a total of $67.00M. The latest funding stage is Series B.
Top alternatives and competitors to Stemedica Cell Technologies, Inc include ViaCyte, Lineage Cell Therapeutics, Cell BioEngines, Inc, MiNK Therapeutics, Luminary Therapeutics, Inc. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Stemedica Cell Technologies, Inc and ViaCyte are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Stemedica Cell Technologies, Inc and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy